IN THE SPOTLIGHT

China's HER2-Targeted ADC Trastuzumab Rezetecan Gains NMPA Approval for HER2-Mutant NSCLC

China's HER2-Targeted ADC Trastuzumab Rezetecan Gains NMPA Approval for HER2-Mutant NSCLC

FDA Grants Priority Review to Sevabertinib in HER2-Mutant NSCLC

FDA Grants Priority Review to Sevabertinib in HER2-Mutant NSCLC

FDA OKs Companion Test for Telisotuzumab Vedotin in NSCLC

FDA OKs Companion Test for Telisotuzumab Vedotin in NSCLC

FDA Approves Emrelis for High c-Met Protein Overexpressing NSCLC

FDA Approves Emrelis for High c-Met Protein Overexpressing NSCLC

Advancements in EGFR+ NSCLC Treatment: MARIPOSA and COCOON

Advancements in EGFR+ NSCLC Treatment: MARIPOSA and COCOON

Teliso-V Plus Osimertinib Active, Tolerable in TKI-Resistant NSCLC

Teliso-V Plus Osimertinib Active, Tolerable in TKI-Resistant NSCLC

Conference MDAngle: ASCO 2025 Advanced NSCLC

Conference MDAngle: ASCO 2025 Advanced NSCLC

ASCO 2025: Previewing Therapeutic Updates in Advanced NSCLC

ASCO 2025: Previewing Therapeutic Updates in Advanced NSCLC

Disease Reassessment at First Progression and Treatment Options for Resistance Mechanisms in EGFR-mutant NSCLC

Disease Reassessment at First Progression and Treatment Options for Resistance Mechanisms in EGFR-mutant NSCLC

A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models

A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models